Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax Completes Enrollment in PEARL 2, the Second of Four Phase 3 Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients
November 21st, 2008
Affymax, Inc. (Nasdaq:AFFY) announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe. "With PEARL 2 fully enrolled, we have now completed enrollment in our pivotal Phase 3 non-dialysis trials," said Anne-Marie Duliege, M.D., chief medical officer at Affymax. "We are now focusing our attention on finalizing...
Source: Health Business Week (2008-11-21)
|
